Helix vs Natera
Natera holds the stronger position because a giant would be blocked from copying its core testing business, while Helix faces both named competitors and a copy risk that Natera does not.
Helix
Helix runs population genomics tests and licenses linked clinical-genomic data to health systems and drug makers
Natera
Natera runs genetic tests for cancer monitoring, prenatal screening, and organ transplant health
Dimension by dimension
| Dimension | Helix | Natera |
|---|---|---|
| Staying power of the core product | Helix is rated protection under test, reflecting genuine uncertainty about its long-term footing. | Natera is rated hard to displace, the strongest standing category available. |
| Exposure to AI absorbing the product | AI is unlikely to absorb Helix's population-scale sequencing and licensing model. | AI is unlikely to absorb Natera's genetic testing business as well. |
| How easily a giant could copy them | A giant copying Helix's data-licensing model is marked possible. | A giant copying Natera's testing business is marked blocked. |
| Pressure from rivals | Helix faces named competition from Tempus and GeneDx for pharma-licensing and health-system deals, though no direct customer loss is documented. | Natera shows no meaningful customer loss and no named rival pressure in the evidence. |
| Financial footing | Helix's evidence shows data volume and partner counts rather than revenue figures. | Natera posted $2.3B in FY2025 revenue, up 35%, with Q1 2026 revenue up 38.8% and raised full-year guidance. |
| Growth trajectory | Helix aims to grow its GenoSphere records from over 500,000 to 1 million within 18 months. | Natera's revenue guidance for FY2026 was raised to $2.74-$2.82B, building on already strong growth. |
Questions people ask
- Is Helix or Natera in a stronger position against AI disruption?
- Both are rated unlikely to have their core product absorbed by AI. The gap between them comes from other pressures, not AI exposure itself, where Natera is better shielded overall.
- Does Helix or Natera face more competition?
- Helix faces named pressure from Tempus and GeneDx competing for pharma-licensing and health-system deals. Natera shows no documented customer loss or named competitive pressure in the evidence.
- How do Helix and Natera compare financially?
- Natera reported $2.3B in FY2025 revenue with 35% year-over-year growth and raised its FY2026 guidance after a strong first quarter. Helix's evidence includes data partnership and record counts but no comparable revenue figures.
- Which company is safer for the long run, Helix or Natera?
- Natera is rated hard to displace while Helix is rated protection under test. That difference in standing, combined with Natera's blocked copy risk, puts Natera ahead in long-term positioning.
Other comparisons with these companies